Our recent study showing highly recurrent loss of function of DLC1 (deleted in liver cancer 1), a tumor suppressor gene in primary prostate carcinoma (PCA), implicates this gene in the pathogenesis of this disease. To evaluate the response of PCA to oncosuppressive activity of DLC1, we examined now the effects of adenoviral vector for human DLC1 transduction into the DLC1-deficient, androgen-independent (AI) and aggressive human PCA cell lines PC-3 and C4-2-B2. Adenovirus-mediated restoration of DLC1 expression inhibited the proliferation, invasiveness and anchorage-independent growth of PC-3 and C4-2-B2 cells in vitro as well as the tumorigenicity of PC-3 cells in nude mice. It also induced cell-cycle arrest, inhibited the activation of RhoA and the formation of actin stress fibers. DLC1 induced apoptosis in C4-2-B2 cells, whereas it did not elicit such an effect in PC-3 cells. The abundance of the antiapoptotic protein Bcl-2 was greater in PC-3 cells than in C4-2-B2 cells, and PC-3 cells were rendered sensitive to DLC1-induced apoptosis by treatment with the Bcl-2 inhibitor HA14-1. These results suggest that adenovirus-mediated DLC1 transfer, alone or together with other agents, such as inhibitors of Bcl-2 or histone deacetylase, might prove effective in the treatment of aggressive, AI-PCA.
Introduction
Despite progress in early detection and therapy, prostate cancer (PCA) continues to be the second leading cause of cancer-related deaths in men. 1 In contrast to most other forms of cancer, the risk of developing PCA increases significantly with age. In developed countries, due to a boom in the aging population and western-style diet resulted in a marked increase in the incidence of PCA. 2, 3 Screening based on the level of prostate-specific antigen (PSA) in serum has enabled the early detection of PCA in men with locally confined tumors that are treatable with surgery, hormone ablation or radiation therapy.
However, in about one-third of patients who undergo radical prostatectomy, the tumors recur, become androgen independent (AI), and adopt an aggressive phenotype characterized by preferential metastasis to bone. [4] [5] [6] The existing therapy for metastasis of PCA is unsatisfactory, with the condition being invariably fatal. [6] [7] [8] The development of novel therapies, possibly including gene therapy, for management of PCA is thus a clinical priority.
Chromosomal regions that are frequently deleted in cancer contain tumor suppressor genes whose loss or inactivation contributes to deregulation of cell proliferation. Prostate carcinoma (PCA), like several other types of solid tumor or lymphoma, exhibits recurrent loss of DNA copy number and loss of heterozygosity at chromosomal region 8p21-22. 9, 10 This region contains the gene DLC1 (deleted in liver cancer 1), which functions as a bona fide tumor suppressor gene in several common cancers and encodes a Rho GTPase-activating protein (Rho-GAP). Reactivation of DLC1 function results in suppression of tumor cell proliferation and induction of apoptosis in vitro as well as prevention of or a reduction in tumorigenicity in vivo. 11 The recent identification of recurrent functional alterations of DLC1 in primary PCA has also implicated this tumor suppressor gene in the pathogenesis of PCA. 12 Downregulation or loss of DLC1 protein expression resulting from methylation of the DLC1 promoter or the deacetylation of histones associated with the gene was also detected in a substantial proportion of individuals with PCA or benign prostatic hyperplasia as well as in PCA cell lines. Methylation of DLC1 correlated with the age of patients with PCA and with the blood level of PSA in those with benign prostatic hyperplasia. 12 Given that loss of function of tumor suppressor genes is directly related to carcinogenesis, these genes have been targeted for the development of anticancer therapeutics. The introduction of tumor suppressor genes into cancer cells prevents tumor growth and, in many instances, yields a complete response without toxicity to normal cells. [13] [14] [15] To assess the feasibility of DLC1-based gene therapy, we have now examined the effects of restoration of DLC1 expression in human PCA cell lines on cell proliferation in vitro and in vivo. Given that adenoviral vectors are considered appropriate vehicles for gene therapy, allowing a high efficiency of gene transfer and a high level of transgene expression 16, 17 we constructed an adenoviral vector harboring human DLC1 cDNA for gene transduction in PCA cells. Adenovirus-mediated restoration of DLC1 expression resulted in suppression of cell proliferation and tumorigenesis as well as in induction of apoptosis or cell-cycle arrest in aggressive, AI-PCA cells.
Materials and methods

Cell lines and culture conditions
The human PCA cell lines LNCaP and PC-3 and the human kidney epithelial cell line 239A were obtained from American Type Culture Collection (Rockville, MD, USA) and were cultured in RPMI 1640 or Dulbecco's modified Eagle's medium (Invitrogen), respectively, each supplemented with 10% heat-inactivated fetal bovine serum. The AI metastatic PCA cell line C4-2-B2 was obtained from ViroMed (Minneapolis, MN) and was cultured in T-medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum. All cells were maintained at 37 1C in a humidified incubator containing 5% CO 2 .
Real-time polymerase chain reaction analysis Real-time polymerase chain reaction analysis of DLC1 mRNA was performed with an ABI Prism 7900 Sequence Detection System (Perkin-Elmer Applied Biosystems, Foster City, CA, USA), as described previously. 12 The amount of DLC1 mRNA was normalized by that of glyceraldehyde-3-phosphate dehydrogenase mRNA.
Vector construction and adenovirus production An adenovirus harboring DLC1 cDNA was prepared with a Viral Power Adenovirus Expression System (Invitrogen) according to the Gateway method. In brief, the full-length cDNA was subcloned into the pENTR/ D-TOPO vector with the use of a pENTR Directional TOPO Cloning Kit (Invitrogen). The cDNA insert was then transferred to the pAd/CMV/V5-DEST vector (Invitrogen) by means of the Gateway system and with the use of LR Clonase (Invitrogen), and the resulting plasmid was purified and digested with PacI (New England Biolabs, Beverly, MA, USA). The linearized plasmid (1-2 mg) was mixed with 3 ml of Lipofectamine 2000 (Invitrogen) in 250 ml of Opti-MEM medium (Invitrogen), and the mixture was added to subconfluent 293A cells cultured in 1 ml of Opti-MEM in six-well plates. The Ad-DLC1 vector produced by the transiently transfected 293A cells was amplified by infection of a fresh batch of 293A cells. The pAd/CMV/V5-GW/lacZ vector (Invitrogen) was digested with PacI and introduced into 293A cells by transfection to produce the Ad-LacZ vector as a control. Both Ad-DLC1 and Ad-LacZ were purified with the use of a Viralbind Adenovirus Purification Kit (Cell Biolabs, San Diego, CA, USA) and stored at À80 1C. The viral titer (plaque-forming units (PFU)) was determined with 293A cells.
Adenovirus infection in vitro C4-2-B2 or PC-3 cells were seeded at 70-80% confluency 1 day before infection. Either Ad-DLC1 or Ad-LacZ was added to the wells at a multiplicity of infection (MOI) of 10 or 50, and the cells were incubated with the viruses for 6 or 18 h, respectively. The virus-containing medium was then removed, and the cells were washed once with phosphate-buffered saline (PBS) and cultured in complete RPMI 1640 or T-medium, respectively, for 48 h before experiments.
Immunoblot analysis
Cells were lysed with NP-40 Lysis Buffer (BioSource, Camarillo, CA, USA) containing a Protease Inhibitor Cocktail (Sigma Aldrich, St Louis, MO, USA). Lysates were centrifuged at 12 000 g for 10 min at 4 1C to remove debris, and the protein concentration of the resulting supernatants was determined with the BCA protein assay (Pierce, Rockford, IL, USA). Equal amounts of supernatant protein were fractionated by SDS-polyacrylamide gel electrophoresis on a 4-12% gradient gel (Invitrogen), transferred to a nitrocellulose membrane (Invitrogen) and probed with antibodies to DLC1, Bcl-2, Bax, caspase-3 and glyceraldehyde 3-phosphate dehydrogenase (Santa Cruz, San Diego, CA, USA). Immune complexes were detected with horseradish peroxidase-conjugated secondary antibodies and a chemiluminescent substrate (Millipore, Billerica, MA, USA).
Assay of cell proliferation and viability Cells were seeded in 96-well plates and infected with Ad-DLC1 or Ad-LacZ. The cell proliferation assay was preformed with the Cell Proliferation Kit I (MTT), according to manufacturer's instructions (Roche, Indianapolis, IN, USA). Absorbance was measured at 490 nm with the use of a microplate reader (Molecular Devices, Sunnyvale, CA, USA). For assay of cell viability, cells were seeded in 24-well plates, infected with Ad-DLC1 or Ad-LacZ and incubated for various times before exposure to trypsin. The number of viable cells was determined with the use of a Cellometer (Nexcelom Bioscience, Lawrence, MA, USA). In some experiments, the cells were incubated in the presence of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA14-1) (Biomol International, Plymouth Meeting, PA, USA) before determination of cell viability. Assay of caspase-3 activity Caspase-3 activity in lysates of cells infected with Ad-LacZ or Ad-DLC1 was measured with an assay kit (Chemicon) based on the spectrophotometric detection of the chromophore p-nitroaniline (p-NA) generated by cleavage of the labeled substrate DEVD-pNA.
Detection of apoptosis
Assay of anchorage-independent cell growth Colony formation in soft agar was evaluated with the use of a Cell Transformation Detection Assay Kit (Chemicon International, Billerica, MA, USA). Cells infected with Ad-LacZ or Ad-DLC1 were suspended in 0.35% low-melting-point agarose and were plated at a density of 2 Â 10 4 per well on the layer of a six-well culture plate containing 0.8% agarose, according to the manufacturer's instructions. The number of colonies with a diameter of 4100 mm was counted after culture for 3 weeks.
Cell invasion assay
Assay of cell invasion was performed with the use of transwell chambers (Becton Dickinson, Franklin Lakes, NJ, USA). In brief, cells infected with Ad-DLC1 or Ad-LacZ were plated at a density of 1 Â 10 6 per well on ECMatrix gel-coated inserts (pore size, 8 mm; Becton Dickinson) and cultured for 24 h. The noninvading cells and the ECMatrix gel were removed from the upper surface of the insert with a cotton-tipped swab, and the invading cells on the lower surface of the membrane were stained by dipping the insert in DiffQuick (Dade Behring, Newark, DE, USA). The insert was examined with a light microscope, and five fields were evaluated for invading cells.
In vivo tumorigenesis assay PC-3 or C4-2-B2 cells infected with Ad-DLC1 or AD-LacZ were harvested with trypsin and resuspended in sterile PBS at a density of 1 Â 10 7 ml
À1
, and 200 ml of the cell suspension were injected subcutaneously into the flank of 6-week-old male nude mice. The diameter of the resulting tumors was measured with calipers every 3 days, and the tumor volume was calculated as the volume of a sphere.
Assay of RhoA activity and staining of cells for F-actin PC-3 or C4-2-B2 cells were infected with Ad-DLC1 or Ad-LacZ, deprived of serum for 24 h and then stimulated with lysophosphatidic acid (LPA) for 20 min. The amount of active RhoA in cell lysates was then measured with the use of a G-LISA kit (Cytoskeleton, Denver, CO, USA). Alternatively, NIH 3T3 cells similarly infected with adenoviruses and stimulated with LPA were fixed with 4% formaldehyde in PBS for 20 min at 37 1C and then stained with rhodamine-conjugated phalloidin (Molecular Probes, Eugene, OR, USA). The cells were examined with a laser-scanning confocal microscope (LSM 510, Carl Zeiss, Thornwood, NY, USA).
Results
Adenovirus-mediated restoration of DLC1 expression
To examine the effects of adenovirus-mediated DLC1 transduction in PCA cells, we selected the PC-3 and C4-2-B2 cell lines, both of which are aggressive, AI-and DLC1-deficient. PC-3 cells form tumors in nude mice, whereas C4-2-B2 cells metastasize to bone in these animals and were established from LNCaP, an androgen-dependent and nonmetastatic PCA cell line. 4 To determine whether the acquisition of metastatic potential was associated with a change in DLC1 expression, we examined the expression of this gene in LNCaP and C4-2-B2 cells. Reverse transcription and real-time polymerase chain reaction analysis showed that the amount of DLC1 mRNA in the nonmetastatic LNCaP cells was about five times that in the metastatic C4-2-B2 cells (Figure 1a ). DLC1 immunoreactivity was not detected in PC-3 or C4-2-B2 cells by immunoblot analysis (Figure 1b) . Infection with a recombinant adenovirus encoding human DLC1 (Ad-DLC1) at an MOI of 10 or 50 conferred a high level of DLC1 expression in both cell lines, whereas infection with the control adenovirus Ad-LacZ had no such effect (Figure 1b) .
Effects of DLC1 on cell growth and viability
The effects of restoration of DLC1 expression on PCA cell growth and viability were evaluated at 24-h intervals over a period of 4 days after infection with Ad-DLC1. Infection with Ad-DLC1 at 50 MOI resulted in marked inhibition of the proliferation of both C4-2-B2 and 
Induction of apoptosis by DLC1
Given the effects of DLC1 on cell proliferation and viability, we next examined whether Ad-DLC1 infection induced apoptosis in the PCA cells. Cells in the early stage of apoptosis were detected by staining with annexin V and propidium iodide. Flow cytometry revealed that infection of C4-2-B2 cells with Ad-DLC1 at 50 MOI induced a marked increase in the percentage of apoptotic (annexin V-positive, propidium iodide-negative) cells compared with that apparent for Ad-LacZ-infected or noninfected control cells, whereas restoration of DLC1 expression in PC-3 cells did not have such an effect (Figure 3a) . Activation of caspases has a central role in apoptosis, and DLC1-mediated inhibition of liver, ovarian or lung cancer cell proliferation was previously shown to be associated with the induction of apoptosis mediated by caspase-3. [18] [19] [20] Consistent with these previous observations, infection with Ad-DLC1 induced an approximately 2.5-fold increase in caspase-3 activity in C4-2-B2 cells (Figure 3b) .
Given that the balance between the antiapoptotic protein Bcl-2 and the proapoptotic protein Bax determines cell survival or death after exposure to an apoptotic stimulus, 21 we examined the possible effects of DLC1 on the amounts of these proteins in PCA cells by immunoblot analysis. Infection with Ad-DLC1 resulted in a MOI-dependent reduction in the amount of Bcl-2 in C4-2-B2 cells, whereas restoration of DLC1 expression had no effect on the abundance of Bcl-2 in PC-3 cells (Figure 4a ). In contrast, DLC1 had no apparent effect on the amount of Bax in either cell line (Figure 4a) . Restoration of DLC1 expression in liver cancer cells was previously shown to result in downregulation of Bcl-2 without an effect on Bax abundance. 19 Immunoblot analysis also confirmed that DLC1 induced cleavage of the precursor form of caspase-3 in C4-2-B2 cells, but not in PC-3 cells (Figure 4b ).
Role of Bcl-2 in DLC1-induced apoptosis
Given that the constitutive level of Bcl-2 expression in PC-3 cells was higher than that in C4-2-B2 cells (Figure 4a ), we next examined whether this difference might be responsible for the difference in sensitivity of the two cell lines to DLC1-induced apoptosis. We, therefore, investigated whether the Bcl-2 inhibitor HA14-1 might sensitize PC-3 cells to the induction of apoptosis by DLC1. Treatment with 10 mM HA14-1 for 4 h resulted in a marked increase in the incidence of apoptosis in PC-3 cells infected with Ad-DLC1, but not in noninfected cells (Figure 5a ). This combined effect of DLC1 and HA14-1 was also apparent in the cell-survival assay (Figure 5b ) and was accompanied by cleavage of the precursor form of caspase-3 ( Figure 5c ).
Oncosuppressive effect of DLC1 in PCA cells
To determine whether restoration of DLC1 expression exerts antioncogenic activity in PCA cells, as it has been shown to do in breast, liver and lung cancers, 11 we first investigated the effects of Ad-DLC1 infection on C4-2-B2 and PC-3 cell invasiveness and growth in semisolid medium. Quantification of anchorage-independent cell growth on the basis of the number and size of colonies formed in soft agar revealed that restoration of DLC1 expression inhibited such growth by 84 and 81% in C4-2-B2 and PC-3 cells, respectively (Figures 6a and b) . A transwell invasion assay also revealed that DLC1 inhibited the invasive activity of both C4-2-B2 and PC-3 cells by approximately 50% (Figures 6c and d) .
We next tested the effect of Ad-DLC1 infection on tumorigenicity of PCA cells in vivo. Restoration of DLC1 expression resulted in marked inhibition of the growth of tumors formed by PC-3 cells in nude mice. All five mice injected with PC-3 cells infected with Ad-LacZ developed tumors, whereas three of the five mice injected with PC-3 cells infected with Ad-DLC1 had not developed tumors after 40 days of observation. The size of those two tumors developed after infection with Ad-DLC1 were less than a half the size of tumors formed in mice infected with Ad-LacZ (Supplementary information). The anchorage-independent growth of C4-2-B2 cells in vitro was previously shown to reflect the in vivo growth and metastatic potential of these cells. 4 Under our conditions, however, using a different strain of mice, we did not detect the formation of tumors by C4-2-B2 cells after 10 weeks of observation. This discrepancy may be due to our use of a different strain Effects of DLC1 on cell-cycle distribution, RhoA activity and the actin cytoskeleton To gain insight into the mechanism of the oncosuppressive effect of DLC1 in PCA cells, we first examined cell-cycle distribution. Arrest of cell-cycle progression contributes to the inhibition of tumor cell growth, migration or invasion. Flow cytometric analysis of cells stained with propidium iodide revealed that Ad-DLC1 infection induced arrest of PC-3 cells at the G 2 -M transition of the cell cycle, whereas it resulted in G 1 arrest as well as the accumulation of cells with a sub-G 1 DNA content (corresponding to apoptotic cells) in C4-2-B2 cells (Figure 7a) .
In liver cancer cells, DLC1 was shown to increase the hydrolysis of GTP bound to RhoA and, to a lesser extent, that bound to Cdc42, but it had only a minimal effect on the GTPase activity of Rac1. 22, 23 We, therefore, examined whether restoration of DLC1 expression affected the activation status of RhoA in PCA cells. PC-3 and C4-2-B2 cells were deprived of serum and then stimulated with LPA for 20 min, after which the amount of the GTPbound (activated) form of RhoA coupled with a Rhotekin-binding domain peptide was determined. Infection with Ad-DLC1 resulted in a MOI-dependent reduction in the amount of the active form of RhoA in both C4-2-B2 and PC-3 cells relative to that in noninfected cells, whereas infection with Ad-LacZ had no such effect (Figure 7b) .
Given that RhoA regulates the formation of actin stress fibers, we examined the possible effect of forced DLC1 expression on RhoA-mediated cytoskeletal reorganization and changes in cell morphology. Serum-deprived NIH 3T3 cells infected with Ad-LacZ exhibited only a low level of F-actin staining with rhodamine-phalloidin. Treatment of these cells with LPA induced a pronounced increase in the amount of cortical F-actin. The morphology of serum-deprived NIH 3T3 cells infected with Ad-DLC1 did not differ substantially from that of those infected with Ad-LacZ, ectopic expression of DLC1 largely prevented the LPA-induced formation of actin stress fibers (Figure 7c) .
Discussion
We have shown that restoration of DLC1 expression inhibited the proliferation of aggressive, AI-PCA (C4-2-B2 and PC-3) cells, thus expanding the spectrum of common forms of cancer that are sensitive to the antioncogenic function of this tumor suppressor gene. We also found that DLC1 induced apoptosis in the metastatic C4-2-B2 cell line, but not in the nonmetastatic PC-3 line. Loss of chromosome 8p or downregulation of DLC1 expression has been associated with metastatic potential in various clones of liver or breast tumor cell lines as well as with reduced survival both of patients with high-grade gliomas and of hepatitis C virus-positive individuals with hepatocellular carcinoma awaiting liver transplantation. [24] [25] [26] [27] [28] [29] The C4-2-B2 cell line, which metastasizes to bone, was isolated from LNCaP cells, which are androgen-dependent, nontumorigenic and nonmetastatic and possess one methylated DLC1 allele. 4, 12 We have now shown that the amount of DLC1 mRNA in LNCaP cells is about five times that in C4-2-B2 cells. This reduction in DLC1 expression in the metastatic cell line is attributable, at least in part, to loss of copy number of 8p as revealed by karyotype analysis. 4 Similarly, human MDA-MB-231 breast cancer cells selected for the ability to metastasize to bone exhibit a lower level of DLC1 expression compared with clones that are only weakly metastatic or nonmetastatic. 30 These observations with different types of cancer cells are thus indicative of a link between DLC1 deficiency and metastasis that may have prognostic implications with regard to the metastatic potential of primary tumors.
Infection with an adenoviral vector for DLC1 resulted in a high level of protein expression in both PC-3 and C4-2-B2 cells. Restoration of DLC1 expression suppressed cell proliferation, invasion and anchorage-independent growth (an in vitro measure of tumorigenicity) in both cell lines as well as reduced the tumorigenicity of PC-3 cells in vivo. The use of an adenoviral vector as a vehicle for DLC1 gene transfer may therefore hold promise as a therapeutic approach for aggressive and metastatic PCA.
The suppression of cell growth by DLC1 was associated with cell-cycle arrest, and a reduction in RhoA activity in both C4-2-B2 and PC-3 cells and ectopic expression of DLC1 in NIH 3T3 fibroblasts inhibited the LPA-induced formation of actin stress fibers. The Rho-GAP domain of DLC1 is thought to be essential for its growth-inhibitory effect on tumor cells. 22, 23 Recently, in lung cancer cells, DLC1 inhibits prostate cancer cell proliferation M Guan et al the Rho-GAP domain of DLC1 was shown to stimulate the GTPase activity of RhoA as well as that of RhoB, RhoC and Cdc42 and inhibit cell proliferation by both Rho-GAP domain-dependent and -independent mechanisms. 31 DLC1 was also recently shown to interact with members of the tensin family of focal adhesion proteins [32] [33] [34] and demonstrated that suppression of the migration of human lung cancer cells by DLC1 requires cooperation between the Rho-GAP and tensin-binding domains. 34 Our results have revealed differences between C4-2-B2 and PC-3 cells with regard to the effects of DLC1 on cell-cycle progression and the induction of apoptosis. DLC1 thus induced arrest in G 1 and G 2 -M phases of the cell cycle in C4-2-B2 and PC-3 cells, respectively, effects that likely contribute to the inhibition of cell proliferation in each cell line. 35 Furthermore, accumulation of subdiploid (apoptotic) cells was apparent only for C4-2-B2 cells infected with Ad-DLC1.
We previously showed that among Du145, LNCaP, PC-3 and 22Rv1 PCA cell lines, DLC1 was expressed only in Du145 cells and only LNCaP cells exhibited partial methylation of the DLC1 promoter. 12 In the absence of aberrant methylation or genomic deletion of DLC1, DLC1 inhibits prostate cancer cell proliferation M Guan et al we considered histone deacetylation as a mechanism responsible for downregulation of DLC1 expression in PCA cell lines and treated the cells with trichostatin A, an inhibitor of histone deacetylase. This drug restored DLC1 expression in LNCaP and 22Rv1 cells, but was ineffective in PC-3 cells. 12 A study examining the possible factors contributing to the resistance of certain PCA cell lines to cell death induced by another histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) found that Du145 cells were highly sensitive to SAHA-induced death and had no detectable Bcl-2 protein, whereas PC-3 cells were resistant to SAHA-induced death, with SAHA inducing upregulation of Bcl-2 in these cells. Inhibition of Bcl-2 activity with HA14-1 rendered PC-3 cells sensitive to SAHA-induced apoptosis in the absence of caspase-3 or caspase-9 activation, 7 and an antisense oligonucleotide specific for Bcl-2 mRNA also sensitized PC-3 cells to radiation-induced apoptosis and enhanced the radiationinduced activation of caspase-3 and caspase-7. 36 Furthermore, an antisense oligonucleotide that depleted the mRNAs for several members of the Bcl family, including Bcl-2, induced apoptosis in PC-3 cells and enhanced their chemosensitivity to paclitaxel. 37 Consistent with these results, we have now shown that adenovirus-mediated restoration of DLC1 expression induced apoptosis accompanied by the activation of caspase-3 in PC-3 cells only after chemical inhibition of Bcl-2 with HA14-1. The similar response of PC-3 cells to the induction of apoptosis by unrelated antioncogenic factors, chemotherapeutic agents, radiation and a tumor suppressor protein thus indicate that inhibition of Bcl-2 family members is crucial for the induction of apoptosis by different apoptotic stimulus.
In conclusion, our results suggest that silencing of DLC1 signaling is an important event in the progression and metastasis of PCA. The effectiveness of adenovirusmediated restoration of DLC1 expression in suppressing PCA cell proliferation and tumorigenicity suggests that therapy based on DLC1 transfer alone or combined with inhibitors of the antiapoptotic activity of Bcl-2 or histone deacetylase inhibitors 37, [38] [39] [40] may prove beneficial for the treatment of aggressive, AI-PCA. To determine the oncosuppressive effects of DLC1 on primary and/or metastatic tumors in various model systems such as orthopic transplantation, xenografts and intracardiac injection will be used for direct in vivo adenovirus/ DLC1 transfer into the tumor tissue or combined treatment with other agents. 41 Additional insights into the role of DLC1 in the progression of prostate tumorigenesis may come from prostate-specific ablation of DLC1 expression in genetically engineered mice predisposed to PCA development. ) for 20 min. They were then fixed, stained with rhodamine-phalloidin and examined by confocal microscopy. DLC1, deleted in liver cancer 1; LPA, lysophosphatidic acid; MOI, multiplicity of infection; PCA, prostate carcinoma.
